NSW medical devices commercial training program open for early-career postgraduates


Thursday, 10 July, 2014

Expressions of interest are invited for a new training program that will arm early-career postgraduate researchers involved in medical technology and product-related research with the necessary entrepreneurial skills to successfully commercialise a medical technology.

Participants will complete a three-month course, delivered by ATP Innovations via professionals with deep domain expertise in the commercialisation of medical technologies. Expressions of interest will close on 21 July 2014. 

The NSW Government established the Medical Devices Fund to help encourage and support investment in the development and commercialisation of medical devices and related technologies in NSW. As part of this objective, the Office for Health and Medical Research in partnership with ATP Innovations is for the first time offering this training program.

Following completion of the three-month NSW Medical Devices Commercialisation Training Program, up to two candidates will be selected based on merit and performance to participate in a two-year, paid, NSW-QB3 Rosenman Institute Scholar Program in the USA. The program is run by the University of California, San Francisco (UCSF) and the QB3 California Institute for Quantitative Biosciences.

This prestigious program will provide a hands-on opportunity to study and implement skills in medical device development and commercialisation. Candidates will work with clinicians and medical device innovators to develop a technology from concept to commercialisation.

The application guidelines and FAQs are available at http://atp-innovations.com.au/.

Related News

3D-printed films provide targeted liver cancer treatment

Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...

Using your brain at work may ward off cognitive impairment

The harder your brain works at your job, the less likely you may be to have memory and thinking...

Repurposed drugs show promise in heart muscle regeneration

The FDA-approved medications, when given in combination, target two proteins that regulate the...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd